Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 1CNS 1

Conditions

Anemia, Refractory, with Excess of Blasts 255Myelodysplastic Syndromes 228Leukemia, Myeloid, Acute 228Anemia 212Leukemia 205Precursor Cell Lymphoblastic Leukemia-Lymphoma 168Leukemia, Myelomonocytic, Chronic 145Neoplasms 142Leukemia, Lymphocytic, Chronic, B-Cell 116Myeloproliferative Disorders 114Multiple Myeloma 113Lymphoma, Non-Hodgkin 105Thrombocytopenia 100Lymphoma 98Hodgkin Disease 91Anemia, Refractory 81Venous Thromboembolism 77Congenital Abnormalities 77Anemia, Aplastic 77Primary Myelofibrosis 76Lymphoma, Follicular 73Leukemia, Myeloid, Chronic-Phase 70Blast Crisis 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Leukemia, Myeloid, Accelerated Phase 64Lymphoma, Mantle-Cell 63Febrile Neutropenia 62Myelodysplastic-Myeloproliferative Diseases 58Hematologic Neoplasms 56Burkitt Lymphoma 56

Interventions

Rivaroxaban 1Long-Term Synaptic Depression 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dyskinesias × Classical hematology × Clear all
NCT06196918 2024-01-09

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

Nanfang Hospital, Southern Medical University

Phase NA Unknown
320 enrolled
CNSClassical hematology

Glioma, Dyskinesias, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡